Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Abingdon Health PLC ( (GB:ABDX) ) has issued an update.
Abingdon Health has provided a detailed update on its collaboration with German biopharmaceutical firm 4TEEN4 Pharmaceuticals to develop DPP3 InvoSelect, a lateral flow-based companion diagnostic for invobenitug, an antibody therapy targeting life-threatening cardiogenic and septic shock. Acting as legal manufacturer and CDMO partner, Abingdon is aligning assay development, regulatory strategy and scale-up manufacturing with 4TEEN4’s drug development timeline to enable global deployment.
The project showcases Abingdon’s core strengths in lateral flow design, custom reader development, regulatory engagement and synchronised co-development of diagnostics and therapeutics, a complex area that demands tight coordination. Positive endorsements from 4TEEN4 and Abingdon’s leadership underscore the partnership’s progress and highlight the potential for co-developed companion diagnostics to improve patient outcomes and reinforce Abingdon’s positioning in the high-value CDx and med-tech services market.
Spark’s Take on ABDX Stock
According to Spark, TipRanks’ AI Analyst, ABDX is a Neutral.
The score is held back primarily by weak financial quality—ongoing losses, declining gross margin, and negative operating cash flow—despite strong revenue growth. Technicals are supportive of an uptrend, but momentum is very overextended, adding pullback risk. Valuation is neutral-to-weak due to a negative P/E and no dividend support.
To see Spark’s full report on ABDX stock, click here.
More about Abingdon Health PLC
Abingdon Health plc is a UK-headquartered med-tech contract service provider specialising in rapid diagnostic tests and regulatory services for an international customer base. The group’s CDMO arm develops and manufactures lateral flow assays across areas such as infectious disease, clinical testing, companion diagnostics, animal health and environmental testing, supported by in-house regulatory consulting and analytical testing operations in the UK and the U.S.
Average Trading Volume: 229,605
Technical Sentiment Signal: Buy
Current Market Cap: £21.34M
Find detailed analytics on ABDX stock on TipRanks’ Stock Analysis page.